Key result
Combined peritoneal dialysis and hemodialysis is linked to improved LVMI and hemoglobin levels.
Why the study?
Combination therapy with peritoneal dialysis and hemodialysis is feasible and may improve clinical status, but its effects on long-term peritoneal membrane and cardiac function were unclear.
Does combination therapy with PD and HD improve peritoneal membrane and cardiac function in patients with end-stage kidney disease?
Population
30 patients with end-stage kidney disease transitioning from PD to HD
Design
Prospective cohort study
Follow-up
12 or 18 months
Authors
Loading...
May support fluid-related cardiac benefits in ESKD; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=30)
Does combination therapy with PD and HD improve peritoneal membrane and cardiac function in patients with end-stage kidney disease?
Combination therapy with PD and HD improves hemoglobin levels and cardiac function (LVMI, hANP) by adjusting body fluid status in patients with end-stage kidney disease.
Kanda et al. (2017) conducted a cohort in End-stage kidney disease (n=30). Combination therapy with peritoneal dialysis (PD) and hemodialysis (HD) vs. Baseline (0 months) was evaluated on Physical, biochemical, dialysate-to-plasma ratio of creatinine (D/P Cr), arteriovenous fistula (AVF) blood flow, and left ventricular mass index (LVMI). Combination therapy with peritoneal dialysis and hemodialysis significantly improved hemoglobin levels, left ventricular mass index, and human atrial natriuretic peptide compared to baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: